Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension

Figures

• 

  Figure 1. Patient disposition. Data are expressed as number (percentage). The most common reasons for permanent discontinuation from the study are listed. The category “other” includes discontinuations that were due to reasons other than an adverse event, lack of efficacy, voluntary withdrawal, lost to follow‐up, protocol deviation, or pregnancy. Patients could have had more than one reason for discontinuation, but only the primary reason is presented here. AZL‐M indicates azilsartan medoxomil

• 

  Figure 2. Change from baseline (mm Hg) in ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) at week 6. Data are least squares mean (±standard error). Sample sizes are 94, 94, and 101 for the placebo, azilsartan medoxomil (AZL‐M) 40‐mg, and AZL‐M 80‐mg groups, respectively, for each measure. *P≤0.001 vs placebo. † P<.05 vs placebo. BP indicates blood pressure

• 

  Figure 3. Hourly profiles of the 24‐hour systolic blood pressure (BP) at week 6. Double‐blind medication dosing was administered at hour 0. AZL‐M indicates azilsartan medoxomil

• 

  Figure 4. Change from baseline (mm Hg) in clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP) at week 6. Data are least squares mean (±standard error). Sample sizes are 133, 134, and 130 for the placebo, azilsartan medoxomil (AZL‐M) 40‐mg, and AZL‐M 80‐mg groups, respectively, for each measure. *P<.01 vs placebo. BP indicates blood pressure